The estimated Net Worth of Terren S Peizer is at least $36.1 Million dollars as of 9 March 2022. Mr. Peizer owns over 1,192,320 units of BioVie stock worth over $36,087,485 and over the last 6 years he sold BIVI stock worth over $0. In addition, he makes $0 as Chief Executive Officer und Director at BioVie.
Sign up
Mr. Peizer BIVI stock SEC Form 4 insiders trading
Terren has made over 4 trades of the BioVie stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,192,320 units of BIVI stock worth $500,774 on 9 March 2022.
The largest trade he's ever made was buying 1,576,100 units of BioVie stock on 12 November 2019 worth over $788,050. On average, Terren trades about 926,226 units every 224 days since 2018. As of 9 March 2022 he still owns at least 12,487,019 units of BioVie stock.
You can see the complete history of Mr. Peizer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Terren Peizer biography
Terren S. Peizer is Chief Executive Officer, Director of the company. He has served as the Chief Executive Officer and Chairman of the Board of Directors of Catasys, Inc., a healthcare company, since 2003. Mr. Peizer is also the founder, Chairman and CEO NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. In addition to his roles with Catasys and NeurMedix, Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal investment vehicle, and holding company that is the owner of all of his portfolio company interests. Through Acuitas, Mr. Peizer owns Acuitas Capital, LLC, an industry leader in investing in micro and small capitalization equities, having invested over $1.5 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder of, and has held various senior executive positions with, several other publicly-traded growth companies, including having served as Chairman of Cray, Inc. a supercomputer company. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce. The Company believes that Mr. Peizer’s extensive knowledge and experience in the financial and healthcare industries, and his extensive insight and experience with capital markets and publicly traded companies at all stages of development, qualifies him to serve as our CEO and on our board of directors. Mr. Peizer’s compensation, including any base compensation, stock awards, and any incentive compensation, will be determined in the future by the Board.
How old is Terren Peizer?
Terren Peizer is 59, he's been the Chief Executive Officer und Director of BioVie since 2018. There are 5 older and 4 younger executives at BioVie. The oldest executive at BioVie Inc. is Steven Gorlin, 82, who is the Director.
What's Terren Peizer's mailing address?
Terren's mailing address filed with the SEC is 11150 Santa Monica Blvd #1500, Los Angeles, CA 90025, USA.
Insiders trading at BioVie
Over the last 9 years, insiders at BioVie have traded over $352,740 worth of BioVie stock and bought 67,100 units worth $464,015 . The most active insiders traders include Terren S Peizer, Steve Gorlin und Richard J Berman. On average, BioVie executives and independent directors trade stock every 122 days with the average trade being worth of $301,811. The most recent stock trade was executed by Cuong V Do on 4 March 2024, trading 10,000 units of BIVI stock currently worth $28,900.
What does BioVie do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
What does BioVie's logo look like?
Complete history of Mr. Peizer stock trades at BioVie und EVmo Inc
BioVie executives and stock owners
BioVie executives and other stock owners filed with the SEC include:
-
Jonathan M. Adams M.B.A., MBA,
Exec. VP of Liver Disease Program -
Joanne Wendy Kim CPA,
CFO & Corp. Sec. -
Cuong Viet Do M.B.A., MBA,
Pres, CEO & Director -
Mina Sooch,
Independent Director -
Michael Sherman,
Independent Director -
James Lang,
Independent Director -
Hari Kumar,
Independent Director -
Sigmund Rogich,
Director -
Rajah Menon,
Director -
Robert Hariri,
Director -
Steven Gorlin,
Director -
Richard Berman,
Director -
Patrick Yeramian,
Chief Medical Officer -
Penelope Markham,
Chief Scientific Officer -
J. Wendy Kim,
Chief Financial Officer, Corporate Secretary -
Terren Peizer,
Chief Executive Officer, Director -
Jonathan Adams,
President, Chief Operating Officer -
Dr. Joseph M. Palumbo M.D.,
Chief Medical Officer -
Clarence N. Ahlem,
Exec. VP of Neuroscience Product Devel. -
Dr. Christopher L. Reading Ph.D.,
Exec. VP of Neuroscience R&D -
Denise Smith,
Sr. VP of Manufacturing & Devel. -
Dr. Penelope Markham Ph.D.,
Exec. VP of Liver Disease R&D -
R Richard Wieland,
interim CFO -
Julie G Anderson,
Director -
Cuong V Do,
President & CEO -
Steve Gorlin,
Director -
Clarence N. Ahlem,
EVP Neuroscience Product Dev. -
Christopher Reading,
EVP Neuroscience R&D -
Joseph M Palumbo,
Chief Medical Officer